From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples

Thrombosis Research

Volumn 136, Issue 1, 2015, Pages 154-160

  Helin, Tuukka A ^a   Lemponen, Marja ^a   Hjemdahl, Paul ^b   Rönquist Nii, Yuko ^b   Lassila, Riitta ^c   Joutsi Korhonen, Lotta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Anticoagulants; Blood Coagulation Tests; Dabigatran Etexilate; Drug; Monitoring; Thrombin Generation

Indexed keywords

D DIMER; DABIGATRAN; FIBRINOGEN; THROMBIN; ANTITHROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG MONITORING; HUMAN; HYPERCOAGULABILITY; LAG TIME; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; THROMBIN TIME; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; METABOLISM;

ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DABIGATRAN; DRUG MONITORING; FEMALE; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; THROMBIN; THROMBIN TIME;

EID: 84931570159     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.032     Document Type: Article

References (36)

1. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151 10.1056/NEJMoa0905561
2. C. Dansirikul, T. Lehr, K. Liesenfeld, S. Haertter, and A. Staab A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery Thromb Haemost 107 2012 775 785 10.1160/TH11-09-0656
3. B. Salmela, L. Joutsi-Korhonen, E. Armstrong, and R. Lassila Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis Semin Thromb Hemost 38 2012 23 30 10.1055/s-0031-1300948
4. T. Baglin, D. Keeling, and S. Kitchen Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology Br J Haematol 159 2012 427 429 10.1111/bjh.12052
5. W.E. Dager, R.C. Gosselin, S. Kitchen, and D. Dwyre Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study Ann Pharmacother 46 2012 1627 1636 10.1345/aph.1R179
6. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J Thromb Haemost 11 2013 756 760 10.1111/jth.12149
7. T.A. Helin, A. Pakkanen, R. Lassila, and L. Joutsi-Korhonen Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories Clin Chem 59 2013 807 814 10.1373/clinchem.2012.198788
8. J. Douxfils, J.M. Dogné, F. Mullier, B. Chatelain, Y. Rönquist-Nii, and R.E. Malmström Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate Thromb Haemost 110 2013 543 549 10.1160/TH13-03-0202
9. J.P. Antovic, M. Skeppholm, J. Eintrei, E.E. Boija, L. Söderblom, and E.M. Norberg Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma Eur J Clin Pharmacol 69 2013 1875 1881 10.1007/s00228-013-1550-4
10. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate- A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127 10.1160/TH09-11-0758
11. G. Nowak The ecarin clotting time, a universal method to quantify direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003 173 183
12. U. Lange, G. Nowak, and E. Bucha Ecarin chromogenic assay- A new method for quantitative determination of direct thrombin inhibitors like hirudin Pathophysiol Haemost Thromb 33 2003 184 191
13. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogné Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb Haemost 107 2012 985 997 10.1160/TH11-11-0804
14. B. Salmela, L. Joutsi-Korhonen, E. Saarela, and R. Lassila Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant Thromb Res 125 2010 538 544 10.1016/j.thromres.2010.02.002
15. A. Calatzis, D. Peetz, S. Haas, M. Spannagl, K. Rudin, and M. Wilmer Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors Am J Clin Pathol 130 2008 446 454 10.1309/Q0G21Y26UR0UHQ1A
16. E.J. Favaloro, G. Lippi, and J. Koutts Laboratory testing of anticoagulants: the present and the future Pathology 43 2011 682 692 10.1097/PAT.0b013e32834bf5f4
17. G. Hafner, K. Fickenscher, H.J. Friesen, H.J. Rupprecht, U. Konheiser, and W. Ehrenthal Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma Thromb Res 77 1995 165 173
18. H.C. Hemker, P. Giesen, R. Al Dieri, V. Regnault, E. de Smedt, and R. Wagenvoord Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 2003 4 15
19. M.M. Samama, L. Le Flem, C. Guinet, G. Gerotziafas, and F. Depasse Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants J Thromb Haemost 5 2007 2554 2556
20. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, and J.W. Eikelboom The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J Am Coll Cardiol 63 2014 321 328 10.1016/j.jacc.2013.07.104
21. Y. Dargaud, A.S. Wolberg, R. Luddington, V. Regnault, H. Spronk, and T. Baglin Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study Thromb Res 130 2012 929 934 10.1016/j.thromres.2012.07.017
22. T.L. Lindahl, F. Baghaei, I.F. Blixter, K.M. Gustafsson, L. Stigendal, and M. Sten-Linder Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2011 371 378 10.1160/TH10-06-0342
23. R. Herrmann, J. Thom, A. Wood, M. Phillips, S. Muhammad, and R. Baker Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban Thromb Haemost 111 2014 989 995 10.1160/TH13-07-0607
24. P.C. Wong, A. White, and J. Luettgen Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay Hosp Pract 2013 41 1995 19 25 10.3810/hp.2013.02.1009
25. E. Perzborn, S. Heitmeier, U. Buetehorn, and V. Laux Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo J Thromb Haemost 12 2014 1054 1065 10.1111/jth.12591
26. G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement Thromb Res 127 2011 457 465 10.1016/j.thromres.2011.01.001
27. L. Green, A.S. Lawrie, R. Patel, R.C. Stephens, I.J. Mackie, and A. Chitolie The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters Thromb Res 130 2012 775 779 10.1016/j.thromres.2011.12.023
28. J.J. van Veen, A. Gatt, and M. Makris Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142 2008 889 903 10.1111/j.1365-2141.2008.07267.x
29. C. Mattsson, A. Menschik-Lundin, S. Nylander, E. Gyzander, and J. Deinum Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro Thromb Res 104 2001 475 486
30. C.T. Ammollo, F. Semeraro, F. Incampo, N. Semeraro, and M. Colucci Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor J Thromb Haemost 8 2010 790 798 10.1111/j.1538-7836.2010.03739.x
31. A.J. ten Cate-Hoek, A.W. Dielis, H.M. Spronk, R. van Oerle, K. Hamulyák, and M.H. Prins Thrombin generation in patients after acute deep-vein thrombosis Thromb Haemost 100 2008 240 245
32. S. Zuily, K. Ait Aissa, A. Membre, V. Regnault, T. Lecompte, and D. Wahl Thrombin generation in antiphospholipid syndrome Lupus 21 2012 758 760 10.1177/0961203312440059
33. M. Benyo, T. Flasko, Z. Molnar, A. Kerenyi, Z. Batta, and T. Jozsa Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability PLoS One 7 2012 10.1371/journal.pone.0051299 (e51299)
34. R. Loeffen, M.C. Kleinegris, S.T. Loubele, P.H. Pluijmen, D. Fens, and R. van Oerle Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method J Thromb Haemost 10 2012 2544 2554 10.1111/jth.12012
35. R.J. Wagenvoord, J. Deinum, M. Elg, and H.C. Hemker The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin J Thromb Haemost 8 2010 1281 1289 10.1111/j.1538-7836.2010.03822.x
36. D.M. Adcock, R. Gosselin, S. Kitchen, and D.M. Dwyre The effect of dabigatran on select specialty coagulation assays Am J Clin Pathol 139 2013 102 109 10.1309/AJCPY6G6ZITVKPVH